The price of CRNX is predicted to go up 16.5%, based on the high correlation periods with WF. The similarity of these two price pattern on the periods is 94.28%.
CRNX
WF
Up: 16.5%Similarity: 94.28%
CRNX Revenue Forecast
CRNX EPS Forecast
CRNX FAQs
What is bull’s view on CRNX?
CRNX stock is currently trading at $35.88, with a strong bullish outlook supported by a consensus price target of $77.00, indicating a potential upside of over 114%. Analysts are optimistic due to the company's robust cash position of $1.4 billion, sufficient to fund operations through 2029, and key milestones like the NDA acceptance for paltusotine in acromegaly. Recent upgrades and positive earnings surprises further reinforce the bullish sentiment.
What is bear's view on CRNX?
CRNX stock shows bearish signals due to the following reasons:
Technical Indicators: The MACD is negative (-2.14), and the Stochastic Oscillator (K: 31.73, D: 16.68) indicates oversold conditions, suggesting weak momentum.
Valuation Concerns: Despite a recent close at $35.78, the stock's P/E ratio is negative (-8.76), reflecting ongoing losses and potential overvaluation.
Resistance Levels: Fibonacci resistance at $37.07 and $38.45 may limit upward movement, while the pivot at $34.84 could act as support.
Citi analyst David Lebowitz raised the firm's price target on Crinetics to $74 from $70 and keeps a Buy rating on the shares following the Q3 report. Crinetics is building a "powerful endocrinology portfolio and look forward to multiple, inflection-worthy catalysts in the coming year," the analyst tells investors in a research note.